Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
52.36
-0.39 (-0.74%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Biohaven Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
239
Market Cap
5.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBHVN News
- 22 days ago - Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 23 days ago - Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PRNewsWire
- 24 days ago - Biohaven Announces Proposed Public Offering of Common Shares - PRNewsWire
- 24 days ago - Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - PRNewsWire
- 4 weeks ago - Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst - Seeking Alpha
- 4 weeks ago - Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug - Investopedia
- 4 weeks ago - Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - Benzinga
- 4 weeks ago - Biohaven's stock surges as treatment slows progress of neurological disorder - Market Watch